As per the merger, Sarah Cannon and Genospace will use molecular profiling data to more effectively match cancer patients to new therapies in clinical trials. Genospace will offers its precision medicine platform and enhance it to allow analysis of disparate data from clinical and laboratory sources. The technology will be integrated into Sarah Cannon’s network of oncology programs across the United States and United Kingdom.
Additionally, Genospace’s platform provides patient-facing portals and disease-specific communities for patient education.
“Bringing together the expertise of Sarah Cannon’s physicians coupled with our leadership in molecular data integration and interpretation, we can impact the lives of hundreds of thousands of patients,” said Mick Correll, CEO at Genospace.
More articles on health IT:
The most common reasons IT pros are fired
Survey: 30% of CIOs name IT security as top concern for 2017
Study: Patient symptoms ‘inconsistent’ between EMR documentation, self-reported questionnaire
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
